Arbutus Biopharma Corp (ABUS) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 197.85M; Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 197.85M | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-07-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 197.85M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-06-30 | 197.85M | (m) | (m) |
| 2026-03-31 | 197.54M | (m) | (m) |
| 2025-09-30 | 192.32M | (m) | (m) |
| 2025-06-30 | 191.70M | (m) | (m) |
| 2025-03-31 | 191.53M | (m) | (m) |
| 2024-09-30 | 189.49M | (m) | (m) |
| 2024-06-30 | 188.78M | (m) | (m) |
| 2024-03-31 | 188.72M | (m) | (m) |
| 2023-12-31 | 179.49M | (m) | (m) |
| 2023-09-30 | 167.70M | (m) | (m) |
| 2023-06-30 | 167.56M | (m) | (m) |
| 2023-03-31 | 166.13M | (m) | (m) |
| 2022-12-31 | 162.57M | (m) | (m) |
| 2022-09-30 | 156.47M | (m) | (m) |
| 2022-06-30 | 149.95M | (m) | (m) |
| 2022-03-31 | 148.73M | (m) | (m) |
| 2021-12-31 | 148.64M | (m) | (m) |
| 2021-09-30 | 135.27M | (m) | (m) |
| 2021-06-30 | 99.16M | (m) | (m) |
| 2021-03-31 | 96.39M | (m) | (m) |
| 2020-12-31 | 95.58M | (m) | (m) |
| 2020-09-30 | 84.91M | (m) | (m) |
| 2020-06-30 | 80.91M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |